New PPRS sets out UK pricing
This article was originally published in Scrip
From February 1st, pharmaceutical companies will have to reduce the prices of their branded drugs in the UK by 3.9%, and by a further 1.9% from January 1st 2010, says the new pharmaceutical price regulation scheme. Further cuts are to be applied on the first of January in 2011 (0.1%), 2012 (0.2%) and 2013 (0.2%).
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.